Insider buying last 90 days
No open-market insider purchases were filed for CDNA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CDNA insider filing, plotted on the chart in Gekko.Open CDNA in Gekko
NASDAQ: CDNA
CareDx (CDNA) Stock Analysis & Forecast
Oct 12 close
$63.12−0.55 (−0.9%)
Gekko Brief
AI summaryOct 12 closeThis week's news on CareDx is dominated by routine filings: several Form 4 disclosures covering insider share withholdings by CEO John Walter, General Counsel Jeffrey Adam Novack, and Chief Commercial Officer Jessica Meng, each tied to tax obligations on RSU vesting at $66.23 per share, along with a routine quarterly stock grant to director Michael Goldberg in place of cash compensation. One item describes institutional trading sentiment analysis flagging an overweight bias across timeframes for CDNA. No results, guidance, deal or regulatory news appears in this stretch.
CDNA closed at $63.12, down 0.9% on the day, sitting above both its 50-day average of $53.44 and its 200-day average of $30.10, with the shorter average above the longer one. The GekkoIndex reads 53.3, placing the stock in the Neutral zone, up 11.5 over the past five readings. Price stands 14.6% above the Gekko Fair Value of $55.06. Over the past year the stock has returned 328.5%, including a 25.6% gain over the past month.
CareDx next reports earnings on 3 November 2026 after the close, 22 days away and inside a typical 20-trading-day holding window; its last report showed EPS of $0.17 against an estimate of $0.06, with a 23.4% reaction, and it has beaten estimates in 8 of its last 8 quarters. No insider, Congress or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a -7.7% return over 5 years, rising in 2 of them. Six analysts cover the stock, split 3 buy and 3 hold, with a consensus target of $58.83.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
CareDx price vs fair value
Close $63.12200-day averageGekko Fair Value $55.06
CareDx quick facts
- Market cap
- $3.27B
- P/E ratio
- 30.7
- Forward P/E
- 156.3
- EPS, TTM
- $2.08
- Revenue, TTM
- $458.1M
- Profit margin
- 24.2%
- Dividend yield
- —
- Beta
- 2.38
- Volume
- 898,940 avg 1.49M
- 1-year return
- +328.5%
- Typical daily move
- ±6.5%
- Typical 20-day move
- ±13.2%
- 50-day average
- $53.44
- 200-day average
- $30.10
- Next earnings
- Nov 3 after close
- Shares outstanding
- 51.73M
CareDx swing-trade checklist
CareDx scores 1 supportive, 1 mixed and 3 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive1 mixed3 headwinds
- Trendsupportive
Above 50 and 200-day
Close $63.12 is above the 50-day ($53.44) and 200-day ($30.10) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
53.3, Neutral
Reading 53.3 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
14.6% above
Price is 14.6% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−7.7% on average
From this point in the calendar, the next 20 trading days averaged −7.7% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
CareDx stock chart and price history
CareDx closed at $63.12 on Oct 12, 2026, +328.5% over the past year, inside a 52-week range of $13.95 to $72.51.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +25.6%
- 3 months
- +118.2%
- 6 months
- +275.0%
- 1 year
- +328.5%
The full CDNA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CDNA in Gekko
Follow CareDx through every session
Put CDNA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CDNA in GekkoFree for 7 days. No credit card required.
About CareDx
CareDx develops diagnostic and monitoring tools for people who have received organ transplants, along with the clinicians who care for them. Its testing menu centers on donor-derived cell-free DNA analysis, sold under the AlloSure name for kidney, heart and lung transplants, alongside AlloMap Heart, a gene-expression test for heart recipients, and AlloSeq cfDNA for broader blood-based surveillance. The company is also known for HLA typing products such as TruSight HLA, Olerup SSP, QTYPE and AlloSeq Tx, plus AlloSeq HCT for chimerism testing in stem cell transplant patients.
Beyond laboratory testing, CareDx builds software for transplant programs, including Ottr for patient management, XynQAPI for quality and waitlist tracking, and AlloCare, an app aimed at transplant patients themselves. Products reach customers directly and through third-party distributors and sub-distributors. The company has a licensing arrangement with Illumina covering next-generation sequencing products, and it works with Cibiltech SAS to commercialize iBox, a tool for predicting kidney allograft loss after transplant.
CareDx was founded in 1998 under the name XDx, Inc., later adopting its current name in 2014. It is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ under the ticker CDNA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- caredx.com
CareDx GekkoIndex: the smart money zone
CareDx’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.3, in the Neutral zone, up 11.5 points over five sessions.
53.3Neutral
Up 11.5 points over five sessions, from the Distribution zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 23 | +2.4% | +16.0% | ||
| Accumulation | 195 | +1.5% | +7.6% | ||
| Neutral (current zone) | 408 | +1.8% | +6.7% | ||
| Distribution | 55 | +4.4% | +19.9% | ||
| Selling | 1 | Too few readings yet | |||
Average CDNA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the CDNA price, zone by zone.Track CDNA in Gekko
Is CareDx stock overvalued? Gekko Fair Value
CareDx trades 14.6% above Gekko Fair Value of $55.06, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what CareDx shares are worth, recalculated every trading day.
$55.06
Gekko Fair Value, Oct 9, 2026
14.6% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CDNA in Gekko
CareDx insider and Congress trading
No open-market insider purchases were filed for CareDx, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CDNA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CDNA, plotted on the chart in Gekko.Open CDNA in Gekko
Buybacks
CareDx has been buying back its own shares.
- Latest authorization
- $100.0M, Apr 28, 2026
- Bought back, quarter ended Dec 31, 2025
- $12.21M
- As a share of market cap
- 0.37%
From company filings.
CareDx earnings: next date and track record
CareDx reports on Nov 3, 2026, after the close (22 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 22 days away
- EPS estimate
- $0.26
- Revenue estimate
- $122.0M
8 of 8reports beat the EPS estimate
±8.4%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- CareDx reported Q2 2026 results highlighting completion of its transformation into a precision medicine diagnostics company. Key pipeline updates include AlloHeme clinical validation manuscript submitted for peer review, showing 41-day lead time in predicting relapse versus standard of care, with CLIA readiness on track for 2027 commercial launch. HistoMap Kidney advances with new University of Wisconsin data published in Transplantation journal. Strategic acquisition of NavDx integrates specialty oncology expansion.
- Guidance
- AlloHeme commercial launch planned for 2027, pending CLIA readiness completion before year-end. Management targeting reimbursement submissions to private and Medicare payers following clinical publication milestone. No specific revenue or earnings targets disclosed in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $0.17 est $0.06 | $131.9M est $114.1M | +23.4% |
| Apr 28, 2026 | $0.34 est $0.13 | $117.7M est $102.0M | −4.8% |
| Feb 24, 2026 | $0.12 est −$0.01 | $108.4M est $103.3M | −1.8% |
| Nov 4, 2025 | $0.28 est −$0.08 | $100.1M est $102.8M | +11.9% |
| Aug 6, 2025 | $0.10 est −$0.10 | $86.68M est $95.25M | −6.1% |
| Apr 30, 2025 | $0.10 est $0.07 | $84.69M est $84.54M | −16.9% |
| Feb 26, 2025 | $0.18 est $0.15 | $86.58M est $84.56M | +0.8% |
| Nov 4, 2024 | $0.14 est $0.01 | $82.88M est $82.16M | +1.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
CareDx stock forecast and analyst price targets
Analysts’ average 12-month price target for CareDx is $58.83, −6.8% from the last close, from 6 firms rating the stock in the last 90 days.
$58.83consensus 12-month target, −6.8% from the last close
Now $63.12Avg $58.83
Low $21High $74
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | BTIG | $74 | +17.2% |
| Sep 2 | Canaccord Genuity | $65 | +3.0% |
| Aug 6 | BTIG | $60 | −4.9% |
| Aug 3 | Craig-Hallum | $64 | +1.4% |
| Aug 3 | William Blair | — | — |
+6.7%average 20-day move after past Neutral readings
−7.7%average move over the next 20 trading days in the last 5 years
±6.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
CareDx seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, CareDx averaged −7.7% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.9% | 3 of 5 |
| Next 10 trading days | −3.6% | 3 of 5 |
| Next 15 trading days | −6.7% | 2 of 5 |
| Next 20 trading days | −7.7% | 2 of 5 |
| Next 30 trading days | −3.4% | 2 of 5 |
For scale, CDNA’s typical 20-trading-day move in either direction is about 13.2%.
CareDx market cap and key statistics
CareDx’s market cap is $3.27B, with a P/E ratio of 30.7 and revenue of $458.1M over the last twelve months.
Valuation
- Market cap
- $3.27B
- P/E ratio
- 30.7
- Forward P/E
- 156.3
- EPS, TTM
- $2.08
- Gekko Fair Value
- $55.06
Trading
- Volume
- 898,940
- Avg volume, 20 days
- 1.49M
- 52-week high
- $72.51
- 52-week low
- $13.95
- Shares outstanding
- 51.73M
Financials
- Revenue, TTM
- $458.1M
- Profit margin
- 24.2%
- Return on equity
- 29.5%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.38
- Typical daily move
- ±6.5%
- Typical 20-day move
- ±13.2%
CareDx stock news this week
Coverage of CareDx this week reads neutral: 1 positive, 11 neutral and 0 negative headlines.
- Form 4 Caredx Inc For: 11 October By Investing.comInvesting.com South Africa, Oct 12
- Behavioral Patterns of CDNA and Institutional FlowsStock Traders Daily, Oct 6
- CareDx CEO John Walter Withholds 8,511 Shares for Tax on RSU VestingKalkine Media, Oct 6
- A 588-share grant replaces cash pay for CareDx (CDNA) director Michael Goldberg.Stock Titan, Oct 6
- After 8,511 shares were withheld for taxes, CareDx (CDNA) CEO holds 644,937 shares directly.Stock Titan, Oct 6
- Form 4 CareDx, Inc. For: Oct 01 Filed by: Novack Jeffrey AdamStreetInsider, Oct 6
CareDx peers
CareDx’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
CareDx stock FAQ
What is CareDx’s market cap?
CareDx’s market cap is $3.27B at the Oct 12, 2026 close of $63.12, with 51.73M shares outstanding. The shares trade on a P/E ratio of 30.7.
What is the CareDx stock forecast?
The consensus analyst 12-month price target for CareDx is $58.83, −6.8% from the last close. Of the 6 firms that rated the stock in the last 90 days, 3 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is CareDx stock overvalued or undervalued?
On Gekko’s estimate CareDx is overvalued: the Oct 12, 2026 close of $63.12 is 14.6% above Gekko Fair Value of $55.06. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does CareDx report earnings next?
CareDx is expected to report on Nov 3, 2026, after the market closes (22 days away). Analysts expect earnings of $0.26 per share on revenue of $122.0M. CareDx beat the earnings estimate in 8 of its last 8 reports, moving 8.4% on average across the report.
What is CareDx’s 52-week high and low?
CareDx’s 52-week high is $72.51 and its 52-week low is $13.95; it closed at $63.12 on Oct 12, 2026, +328.5% over the past year. Over the last five years the shares peaked at $75.92 on Oct 19, 2021.
Is CareDx stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (trend), 1 as mixed (gekkoindex) and 3 as headwinds (fair value, earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See CareDx the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.